Menu Menu

PEAR 2: Pharmacogenomic Evaluation of Antihypertensive Responses 2

PEAR logo

PEAR2 was a randomized clinical trial where a GWAS study was conducted in 457 hypertensive self-identified Caucasian and African American individuals who received metoprolol 100 mg and chlorthalidone 25 mg in a sequential monotherapy design. Data collected include home and clinic blood pressure, blood samples for testing for adverse metabolic effects and other biomarkers (glucose, insulin, total cholesterol, LDL, HDL, TG, uric acid, potassium, sodium, creatinine, plasma renin activity), RNA, and DNA and urine sample. The data will be used for replication of findings from the PEAR trial, along with new discoveries in order to define genetic determinants of antihypertensive response and adverse metabolic responses.